JB170

JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase.


Cat. No.: EX-A7164	Purity: >98%

	Chemical structure of JB170

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
50mg	712	In-stock
100mg	1185	In-stock
250mg	2050	In-stock
1g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2705844-82-0
Purity	>98%
Formula	C48H44ClFN8O11
Mol Weight	963.361
Color	Light yellow to yellow
State	solid powder
Solubility	Soluble in DMSO 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20℃ 3 years; 4℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Adhikari B, et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. Nat Chem Biol. 2020;16(11):1179-1188.
CoA	CoA of JB170


		Search